Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no ...

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...

Follicular lymphoma is a diverse disease ... The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline ...

PMB-CT01, a BAFF-R targeting CAR-T cell therapy, achieved a 100% complete response rate in relapsed/refractory follicular lymphoma patients. The phase 1 PMB-102 study focuses on safety, optimal dosing ...

recently approved targeted and immunotherapeutic agents and areas of unmet needs in follicular lymphoma. In this video, Brody discusses: Notable advances and FDA approvals, including lenalidomide ...

UNDERSTANDING FOLLICULAR LYMPHOMA: A SLOW-GROWING NON-HODGKIN’S LYMPHOMA Follicular Lymphoma is a subtype of non-Hodgkin lymphoma that originates in white blood cells known as lymphocytes ...

versus Rituxan ® (rituximab) in combination with GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and who are not ...